{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:41:40Z","timestamp":1787020900393,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction\u2013associated steatotic liver disease (MASLD), formerly nonalcoholic fatty liver disease (NAFLD), often coexists with type 2 diabetes mellitus (T2DM) due to shared metabolic pathways such as insulin resistance. Empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, may provide hepatic and metabolic benefits. This study evaluated its effects on liver fat, enzymes, fibrosis, metabolic parameters, and inflammation in T2DM with MASLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis of randomized controlled trials (RCTs) was performed according to PRISMA guidelines. Primary outcomes included liver fat content, enzymes, and fibrosis markers. Secondary outcomes were metabolic and inflammatory parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eleven RCTs (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093077) were included. Empagliflozin significantly reduced liver fat (MD = -3.11%; 95% CI: -4.12 to -2.11;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.00001) and liver stiffness (MD = -0.43\u00a0kPa;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003), but had no significant effect on AST (-0.27 IU\/L;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.89) or GGT (-9.25 IU\/L;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.14). It significantly lowered HbA1c (-0.54%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), fasting glucose (-20.89\u00a0mg\/dL;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), weight (-2.04\u00a0kg;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), and waist circumference (-3.47\u00a0cm;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), with a nonsignificant reduction in BMI (-0.77\u00a0kg\/m\u00b2;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.09).Uric acid decreased (-0.41\u00a0mg\/dL;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.00001), but IL-6 and fibrosis scores (FIB-4, NFS) remained unchanged.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Empagliflozin improves liver fat, stiffness, glycemic control, body weight, and uric acid in T2DM with MASLD, but its effects on fibrosis and inflammation remain uncertain. Larger, long-term histologic trials are needed to confirm these outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13098-025-02084-x","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T07:17:09Z","timestamp":1767856629000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Empagliflozin and its impact on hepatic and metabolic outcomes in patients with type 2 diabetes and NAFLD: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"18","author":[{"given":"Khadeeja Ali","family":"Hamzah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammedsadeq A.","family":"Shweliya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousif Hameed","family":"Kurmasha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marafi Jammaa","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashna","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abanoub I.I.","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarwa","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya Ahmed","family":"Shimal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayar","family":"Moghazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Fahem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Yassin","family":"Al Aboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elgazzar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulhadi M. A.","family":"Mahgoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Saad","family":"Al-Shammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"2084_CR1","doi-asserted-by":"publisher","unstructured":"Kaul K, Tarr JM, Ahmad S, Kohner EM, Chibber R,. Ahmad SI, editors. Diabetes: An Old Disease, a New Insight [Internet]. 2012 Aug 1 [cited 2025 Jun 15];771:1\u201311. Available from: http:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/978-1-4614-5441-0","DOI":"10.1007\/978-1-4614-5441-0"},{"key":"2084_CR2","doi-asserted-by":"crossref","unstructured":"Abenavoli L, Greco M, Milic N, Accattato F, Foti D, Gulletta E et al. Effect of mediterranean diet and antioxidant formulation in nonalcoholic fatty liver disease: A randomized study. Nutrients [Internet]. 2017 Aug 12 [cited 2025 Jun 15];9(8). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28805669\/","DOI":"10.3390\/nu9080870"},{"key":"2084_CR3","doi-asserted-by":"crossref","unstructured":"Muzica CM, Sfarti C, Trifan A, Zenovia S, Cuciureanu T, Nastasa R et al. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship. Can J Gastroenterol Hepatol [Internet]. 2020 [cited 2025 Jun 15];2020. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33425804\/","DOI":"10.1155\/2020\/6638306"},{"key":"2084_CR4","doi-asserted-by":"crossref","unstructured":"Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus \u2014 mechanisms and treatments. Nat Rev Gastroenterol Hepatol [Internet]. 2021 Sep 1 [cited 2025 Jun 15];18(9):599\u2013612. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33972770\/","DOI":"10.1038\/s41575-021-00448-y"},{"key":"2084_CR5","doi-asserted-by":"crossref","unstructured":"Richard J, Lingvay I. Hepatic steatosis and type 2 diabetes: Current and future treatment considerations. Expert Rev Cardiovasc Ther [Internet]. 2011 Mar [cited 2025 Jun 15];9(3):321\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21438811\/","DOI":"10.1586\/erc.11.15"},{"key":"2084_CR6","doi-asserted-by":"crossref","unstructured":"Zhang Y, Liu X, Zhang H, Wang X. Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne) [Internet]. 2022 Feb 24 [cited 2025 Jun 15];13. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35282455\/","DOI":"10.3389\/fendo.2022.836455"},{"key":"2084_CR7","doi-asserted-by":"crossref","unstructured":"Taheri H, Malek M, Ismail-Beigi F, Zamani F, Sohrabi M, Reza babaei M et al. Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With NonAlcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Adv Ther [Internet]. 2020 Nov 1 [cited 2025 Jun 15];37(11):4697\u2013708. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32975679\/","DOI":"10.1007\/s12325-020-01498-5"},{"key":"2084_CR8","doi-asserted-by":"crossref","unstructured":"Chehrehgosha H, Sohrabi MR, Ismail-Beigi F, Malek M, Reza Babaei M, Zamani F et al. Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with NonAlcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Diabetes Therapy [Internet]. 2021 Mar 1 [cited 2025 Jun 15];12(3):843\u201361. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33586120\/","DOI":"10.1007\/s13300-021-01011-3"},{"issue":"2","key":"2084_CR9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.53813","volume":"16","author":"E Koullias","year":"2024","unstructured":"Koullias E, Papavdi M, Athanasopoulos S, Mitrakou A, Deutsch M, Zoumpoulis P, et al. Addition of dulaglutide or empagliflozin to standard-of-care treatment: effect on liver steatosis in patients with type 2 diabetes mellitus. Cureus. 2024;16(2):e53813. https:\/\/doi.org\/10.7759\/cureus.53813.","journal-title":"Cureus"},{"issue":"8","key":"2084_CR10","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","volume":"41","author":"MS Kuchay","year":"2018","unstructured":"Kuchay MS, Krishan S, Mishra SK, Farooqui KJ, Singh MK, Wasir JS, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: A randomized controlled trial (E-LIFT Trial). Diabetes Care. 2018;41(8):1801\u20138.","journal-title":"Diabetes Care"},{"issue":"2","key":"2084_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11020322","volume":"11","author":"A Caturano","year":"2023","unstructured":"Caturano A, Galiero R, Loffredo G, Vetrano E, Medicamento G, Acierno C, et al. Effects of a combination of empagliflozin plus metformin vs. metformin monotherapy on NAFLD progression in type 2 diabetes: the IMAGIN pilot study. Biomedicines. 2023;11(2):322. https:\/\/doi.org\/10.3390\/biomedicines11020322.","journal-title":"Biomedicines"},{"issue":"6","key":"2084_CR12","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/jgf2.723","volume":"25","author":"A Esmaeili","year":"2024","unstructured":"Esmaeili A, Pourahmad Azar R, Mohammad Hosseiniazar M, Hooshmand Gharabagh L. Empagliflozin add-on therapy is superior to metformin monotherapy in diabetic patients with NAFLD: an open-label, single-center, pilot clinical trial. J Gen Fam Med. 2024;25(6):351\u20137. https:\/\/doi.org\/10.1002\/jgf2.723.","journal-title":"J Gen Fam Med"},{"issue":"11","key":"2084_CR13","doi-asserted-by":"publisher","first-page":"107703","DOI":"10.1016\/j.jdiacomp.2020.107703","volume":"34","author":"S Sakurai","year":"2020","unstructured":"Sakurai S, Jojima T, Iijima T, Tomaru T, Usui I, Aso Y. Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: association with improvement of fibrinolysis. J Diabetes Complicat. 2020;34(11):107703.https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107703.","journal-title":"J Diabetes Complicat"},{"issue":"2","key":"2084_CR14","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2337\/dc19-0641","volume":"43","author":"S Kahl","year":"2020","unstructured":"Kahl S, Gancheva S, Stra\u00dfburger K, Herder C, Machann J, Katsuyama H, et al. Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: A randomized, double-blind, phase 4, placebo-controlled trial. Diabetes Care. 2020;43(2):298\u2013305.","journal-title":"Diabetes Care"},{"issue":"3","key":"2084_CR15","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","volume":"12","author":"H Chehrehgosha","year":"2021","unstructured":"Chehrehgosha H, Sohrabi MR, Ismail-Beigi F, Malek M, Reza Babaei M, Zamani F, et al. Empagliflozin improves liver steatosis and fibrosis in patients with Non-Alcoholic fatty liver disease and type 2 diabetes: A Randomized, Double-Blind, Placebo-Controlled clinical trial. Diabetes Therapy. 2021;12(3):843\u201361.","journal-title":"Diabetes Therapy"},{"key":"2084_CR16","doi-asserted-by":"crossref","unstructured":"Jojima T, Sakurai S, Wakamatsu S, Iijima T, Saito M, Tomaru T et al. Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol. Int J Cardiol [Internet]. 2021 May 15 [cited 2025 Aug 17];331:243\u20138. Available from:https:\/\/www.internationaljournalofcardiology.com\/action\/showFullText?pii=S0167527321001455","DOI":"10.1016\/j.ijcard.2021.01.063"},{"issue":"10","key":"2084_CR17","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","volume":"61","author":"N Sattar","year":"2018","unstructured":"Sattar N, Fitchett D, Hantel S, George JT, Zinman B. Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME\u00ae trial. Diabetologia. 2018;61(10):2155\u201363.","journal-title":"Diabetologia"},{"issue":"4","key":"2084_CR18","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2337\/dc23-1646","volume":"47","author":"S Abdelgani","year":"2024","unstructured":"Abdelgani S, Khattab A, Adams J, Baskoy G, Brown M, Clarke G, et al. Empagliflozin reduces liver fat in individuals with and without diabetes. Diabetes Care. 2024;47(4):668\u201375.","journal-title":"Diabetes Care"},{"issue":"1","key":"2084_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12902-025-01882-8","volume":"25","author":"F Shojaei","year":"2025","unstructured":"Shojaei F, Erfanifar A, Kalbasi S, Nikpour S, Gachkar L. The effect of empagliflozin on non-alcoholic fatty liver disease-related parameters in patients with type 2 diabetes mellitus: a randomized controlled trial. BMC Endocr Disorders. 2025;25(1):52.https:\/\/doi.org\/10.1186\/s12902-025-01882-8.","journal-title":"BMC Endocr Disorders"},{"key":"2084_CR20","unstructured":"Mirabelli M, Brunetti A, Choi R, Vemuri J, Poloju A, Raj R et al. Current and Emerging Treatments for Metabolic Associated Steatotic Liver Disease and Diabetes: A Narrative Review. Endocrines 2025, Vol 6, Page 27 [Internet]. 2025 Jun 5 [cited 2025 Jun 14];6(2):27. Available from:https:\/\/www.mdpi.com\/2673-396X\/6\/2\/27\/htm"},{"key":"2084_CR21","doi-asserted-by":"publisher","unstructured":"Malandris K, Papandreou S, Avgerinos I, Karagiannis T, Paschos P, Michailidis T et al. Comparative efficacy of glucose-lowering drugs on liver steatosis as assessed by means of magnetic resonance imaging in patients with type 2 diabetes mellitus: systematic review and network meta-analysis. Hormones [Internet]. 2023 Dec 1 [cited 2025 Jun 14];22(4):655\u201364. Available from:https:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/s42000-023-00493-z","DOI":"10.1007\/s42000-023-00493-z"},{"issue":"1","key":"2084_CR22","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41598-024-83820-7","volume":"15","author":"M Sanjari","year":"2025","unstructured":"Sanjari M, Hadavizadeh M, Sadeghi N, Naghibzadeh-Tahami A. Effect of empagliflozin on weight in patients with prediabetes and diabetes. Sci Rep. 2025;15(1):118.https:\/\/doi.org\/10.1038\/s41598-024-83820-7. Published 2025 Jan 2.","journal-title":"Sci Rep"},{"key":"2084_CR23","doi-asserted-by":"publisher","unstructured":"Lin J, Huang Y, Xu B, Gu X, Huang J, Sun J, et al. Effect of Dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. BMJ. 2025;389(e083735).https:\/\/doi.org\/10.1136\/bmj-2024-083735.","DOI":"10.1136\/bmj-2024-083735"},{"key":"2084_CR24","doi-asserted-by":"publisher","unstructured":"Weng MT, Yang PJ, Liu PF, Chang CH, Lee HS, Sheu JC et al. Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Hepatol Int [Internet]. 2024 Apr 1 [cited 2025 Jun 15];19(2):405\u201314. Available from:https:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/s12072-024-10758-3","DOI":"10.1007\/s12072-024-10758-3"},{"key":"2084_CR25","unstructured":"Dapagliflozin treatment alleviates fatty liver in. patients with type 2 diabetes [Internet]. [cited 2025 Jun 15]. Available from:https:\/\/www.spandidos-publications.com\/10.3892\/br.2024.1904?text=fulltext"},{"key":"2084_CR26","doi-asserted-by":"crossref","unstructured":"Shao SC, Kuo LT, Chien RN, Hung MJ, Lai ECC. SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews. BMJ Open Diabetes Res Care [Internet]. 2020 Dec 2 [cited 2025 Jun 15];8(2):1956. Available from:https:\/\/drc.bmj.com\/content\/8\/2\/e001956","DOI":"10.1136\/bmjdrc-2020-001956"},{"key":"2084_CR27","doi-asserted-by":"crossref","unstructured":"Macaire A, Ong Lopez C, Audrei J, Pajimna T. Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis. Scientific Reports [Internet]. 2024 [cited 2025 Jun 14];14:2122. Available from: https:\/\/www.nature.com\/scientificreports","DOI":"10.1038\/s41598-024-52603-5"},{"key":"2084_CR28","doi-asserted-by":"crossref","unstructured":"Mantovani A, Petracca G, Csermely A, Beatrice G, Targher G, Sodium-Glucose. Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. Metabolites [Internet]. 2020 Jan 1 [cited 2025 Jun 14];11(1):22. Available from:https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7823667\/","DOI":"10.3390\/metabo11010022"},{"key":"2084_CR29","doi-asserted-by":"crossref","unstructured":"Akuta N, Kawamura Y, Fujiyama S, Saito S, Muraishi N, Sezaki H et al. Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study. Hepatol Commun [Internet]. 2022 Sep 1 [cited 2025 Jun 14];6(9):2286\u201397. Available from:https:\/\/pubmed.ncbi.nlm.nih.gov\/35581956\/","DOI":"10.1002\/hep4.2005"},{"key":"2084_CR30","doi-asserted-by":"crossref","unstructured":"Haddad F, Dokmak G, Bader M, Karaman R. A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications. Life 2023, Vol 13, Page 1012 [Internet]. 2023 Apr 14 [cited 2025 Jun 14];13(4):1012. Available from:https:\/\/www.mdpi.com\/2075-1729\/13\/4\/1012\/htm","DOI":"10.3390\/life13041012"},{"key":"2084_CR31","doi-asserted-by":"crossref","unstructured":"Sanjari M, Hadavizadeh M, Sadeghi N, Naghibzadeh-Tahami A. Effect of empagliflozin on weight in patients with prediabetes and diabetes. Sci Rep [Internet]. 2025 Dec 1 [cited 2025 Jun 14];15(1):118. Available from:https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11696924\/","DOI":"10.1038\/s41598-024-83820-7"},{"key":"2084_CR32","doi-asserted-by":"crossref","unstructured":"Ozcelik S, Celik M, Vural A, Aydin B. The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: a real-world data. Northern Clinics of Istanbul [Internet]. 2020 [cited 2025 Jun 14];7:167\u2013173. Available from: https:\/\/www.northernclinicsist.com","DOI":"10.14744\/nci.2019.22697"},{"key":"2084_CR33","doi-asserted-by":"crossref","unstructured":"Taheri H, Chiti H, Reshadmanesh T, Gohari S, Jalilvand A, Arsang-Jang S et al. Empagliflozin improves high-sensitive cardiac troponin-I and high-density lipoprotein cholesterol in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD Trial. J Diabetes Metab Disord [Internet]. 2023 Dec 1 [cited 2025 Jun 14];22(2):1723\u201330. Available from:https:\/\/pubmed.ncbi.nlm.nih.gov\/37975102\/","DOI":"10.1007\/s40200-023-01305-2"},{"key":"2084_CR34","doi-asserted-by":"crossref","unstructured":"Rau M, Thiele K, Korbinian Hartmann NU, M\u00f6llmann J, Wied S, B\u00f6hm M et al. Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study. Atherosclerosis [Internet]. 2021 Aug 1 [cited 2025 Jun 14];330:8\u201313. Available from:https:\/\/pubmed.ncbi.nlm.nih.gov\/34218214\/","DOI":"10.1016\/j.atherosclerosis.2021.06.915"},{"key":"2084_CR35","unstructured":"Hossain MF, Khan NA, Rahman A, Chowdhury MFI, Bari S, Khan MA et al. Empagliflozin Ameliorates Progression From Prediabetes to Diabetes and Improves Hepatic Lipid Metabolism: A Systematic Review. Cureus [Internet]. 2022 Aug 25 [cited 2025 Jun 14];14(8):e28367. Available from:https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9506669\/"},{"key":"2084_CR36","doi-asserted-by":"publisher","first-page":"1389967","DOI":"10.3389\/fimmu.2024.1389967","volume":"15","author":"H Gong","year":"2024","unstructured":"Gong H, He Q, Zhu L, Feng Z, Sun M, Jiang J, et al. Associations between systemic inflammation indicators and nonalcoholic fatty liver disease: evidence from a prospective study. Front Immunol. 2024;15:1389967.","journal-title":"Front Immunol"},{"key":"2084_CR37","doi-asserted-by":"publisher","first-page":"1388557","DOI":"10.3389\/fnut.2024.1388557","volume":"11","author":"X Zhang","year":"2024","unstructured":"Zhang X, Ruan J, He Y, Xu A, Fang Y, Zhang Q, et al. Dietary inflammatory index and the risks of non-alcoholic fatty liver disease: a systematic review and meta-analysis. Front Nutr. 2024;11:1388557.","journal-title":"Front Nutr"},{"key":"2084_CR38","doi-asserted-by":"publisher","unstructured":"Buttice L, Ghani M, Suthakar J, Gnanalingham S, Carande E, Kennedy BWC et al. The effect of sodium-glucose cotransporter-2 inhibitors on inflammatory biomarkers: A meta-analysis of randomized controlled trials. Diabetes Obes Metab [Internet]. 2024 Jul 1 [cited 2025 Jun 14];26(7):2706\u201321. Available from:https:\/\/doi.org\/10.1111\/dom.15586","DOI":"10.1111\/dom.15586"},{"key":"2084_CR39","doi-asserted-by":"crossref","unstructured":"Cao Y, Liang N, Liu T, Fang J, Zhang X. Effect of SGLT2 Inhibitors and Metformin on Inflammatory and Prognostic Biomarkers in Type 2 Diabetes Patients. Endocr Metab Immune Disord Drug Targets [Internet]. 2022 Aug 30 [cited 2025 Jun 14];23(4):530\u201347. Available from:https:\/\/pubmed.ncbi.nlm.nih.gov\/36043731\/","DOI":"10.2174\/1871530322666220827150054"},{"key":"2084_CR40","doi-asserted-by":"crossref","unstructured":"Iqbal F, Shuja MH, Azam L, Amjad M, Manjee KZ, Ramzan H et al. Effect of Sodium-Glucose Cotransporter 2 Inhibitors on the 24-Hour Ambulatory Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension: An Updated Meta-Analysis. Endocrine Practice [Internet]. 2024 May 1 [cited 2025 Jun 14];30(5):481\u20139. Available from:https:\/\/pubmed.ncbi.nlm.nih.gov\/38484937\/","DOI":"10.1016\/j.eprac.2024.03.001"},{"key":"2084_CR41","doi-asserted-by":"crossref","unstructured":"Zanchi A, Pruijm M, Muller ME, Ghajarzadeh-Wurzner A, Maillard M, Dufour N et al. Twenty-Four Hour Blood Pressure Response to Empagliflozin and Its Determinants in Normotensive Non-diabetic Subjects. Front Cardiovasc Med [Internet]. 2022 Mar 22 [cited 2025 Jun 14];9. Available from:https:\/\/pubmed.ncbi.nlm.nih.gov\/35391843\/","DOI":"10.3389\/fcvm.2022.854230"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-025-02084-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-02084-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-02084-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T01:34:02Z","timestamp":1770341642000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13098-025-02084-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2084"],"URL":"https:\/\/doi.org\/10.1186\/s13098-025-02084-x","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}